Digistain - Breast Cancer Companion Diagnostic for over-prescribed chemotherapy

Digistain是一家市场就绪的英国临床诊断公司，致力于改变乳腺癌治疗，以节省时间、金钱和生命。当前的伴随诊断会延迟治疗决策长达一个月，而我们的技术仅需15分钟即可为肿瘤学家提供决策数据。这意味着在适当的情况下可以避免化疗，使患者避免化疗毒性导致的死亡风险增加50%。当需要立即开始化疗时，时间会造成生与死的差异，每延迟30天就会增加死亡的机会。Digistain使肿瘤学家能够跨越目前可用的技术，提供上级护理快速和负担得起的。我们的创始人，博士克里斯菲利普斯和博士Hemmel Amrania持有博士学位，从剑桥和帝国理工学院伦敦分别并已赢得了多个研究奖项，这一创新。Digistain已经在英国领先的癌症治疗中心进行了试验，包括帝国理工学院医疗保健，诺丁汉大学医院NHS信托基金和伦敦玛丽女王大学的Barts癌症研究所。虽然其他风险分析解决方案使用湿化学分析数据的固定评估，Digistain利用机器学习来识别固定算法方法不可见的模式。Digistain从每个活检中捕获独特的光谱特征，并对每个活检的10，000多个数据点进行分析。有了这些信息，Digistain的人工智能过程计算出准确的风险评分，该评分已在英国癌症研究所审查的一项研究中对800多名患者进行了验证。该研究表明，Digistain的临床性能上级现有技术。Digistain与现有最先进的技术相比具有显著优势。目前，肿瘤学家必须等待几周的测试结果。该项目的目的是指导辅助（手术后）治疗决策，以改善患者预后，促进英国经济增长，挽救生命-同时通过让更多患者负担得起来减少护理不平等。

Digistain is a market-ready, UK-based clinical diagnostics company transforming breast cancer treatment to save time, money, and lives.Where current companion diagnostics delay treatment decisions for up to a month, our technology provides oncologists with decision-making data in just 15 minutes. This means chemotherapy can be avoided where appropriate and enables patients to avoid the unnecessary increase in the risk of death caused by chemotherapy toxicity by 50%.When chemotherapy is required and initiated immediately, time makes the difference between life and death with every 30-day delay increasing the chance of death. Digistain enables oncologists to leapfrog currently available technologies to provide superior care quickly and affordably.Our founders, Dr Chris Phillips and Dr Hemmel Amrania hold PhDs from Cambridge and Imperial College London respectively and have won multiple research awards for this innovation already. Digistain has been trialled with leading British cancer treatment centres including Imperial College Healthcare, Nottingham University Hospitals NHS Trust, and Barts Cancer Institute at Queen Mary University London.While other risk profiling solutions use a fixed assessment of data from wet chemistry analysis, Digistain leverages machine learning to identify patterns invisible to fixed algorithmic approaches. Digistain captures a unique spectral signature from each biopsy and performs analysis on over 10,000 data points per biopsy. With this information, Digistain's artificial intelligence process computes an accurate risk score which has been validated on over 800 patients in a study reviewed by Cancer Research UK. The study demonstrated superior clinical performance to the incumbent.Digistain offers a significant advantage over the existing state-of-the-art technology. Currently, oncologists must wait several weeks for test results. The aim of this project is to guide adjuvant (post-surgery) therapy decisions to improve patient outcomes, promote UK economic growth, and save lives -- all while reducing care inequalities by being affordable to more patients.